Literature DB >> 18378714

Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.

John D Cleary1, Guillermo Garcia-Effron, Stanley W Chapman, David S Perlin.   

Abstract

We describe a case of recurring Candida glabrata infection in a 68-year-old African-American female on caspofungin therapy. The initial isolate was susceptible, but isolates recovered during following relapses were not. All isolates were clonal, and high-MIC strains contained a mutation in the highly conserved hot spot 1 region of Fks1p.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18378714      PMCID： PMC2415792          DOI： 10.1128/AAC.01568-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.

Authors:  Morgan Hakki; Janet F Staab; Kieren A Marr
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

2.  Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature.

Authors:  René Pelletier; Isabelle Alarie; Réal Lagacé; Thomas J Walsh
Journal:  Med Mycol       Date:  2005-09       Impact factor: 4.076

Review 3.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

4.  Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.

Authors:  S Park; R Kelly; J Nielsen Kahn; J Robles; M-J Hsu; E Register; W Li; V Vyas; H Fan; G Abruzzo; A Flattery; C Gill; G Chrebet; S A Parent; M Kurtz; H Teppler; C M Douglas; D S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.

Authors:  Varsha Moudgal; Tania Little; Dina Boikov; Jose A Vazquez
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin.

Authors:  Christopher D Miller; Ben W Lomaestro; Steven Park; David S Perlin
Journal:  Pharmacotherapy       Date:  2006-06       Impact factor: 4.705

7.  Multilocus sequence typing of Candida glabrata reveals geographically enriched clades.

Authors:  Andrew R Dodgson; Claude Pujol; David W Denning; David R Soll; Andrew J Fox
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

Review 8.  Caspofungin: first approved agent in a new class of antifungals.

Authors:  Melissa D Johnson; John R Perfect
Journal:  Expert Opin Pharmacother       Date:  2003-05       Impact factor: 3.889

9.  Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.

Authors:  Mikkel Krogh-Madsen; Maiken Cavling Arendrup; Lars Heslet; Jenny Dahl Knudsen
Journal:  Clin Infect Dis       Date:  2006-02-27       Impact factor: 9.079

10.  Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

Authors:  Michel Laverdière; Richard G Lalonde; Jean-Guy Baril; Donald C Sheppard; Steven Park; David S Perlin
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790
View more
  53 in total

1.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

Review 2.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

3.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

4.  Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.

Authors:  Pilar Escribano; Jesús Guinea; María Ángeles Bordallo-Cardona; Laura Judith Marcos-Zambrano; Carlos Sánchez-Carrillo; Elia Gómez G de la Pedrosa; Rafael Cantón; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

5.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

6.  Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

Authors:  M A Pfaller; D J Diekema; L Ostrosky-Zeichner; J H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; M A Ghannoum; C C Knapp; D J Sheehan; T J Walsh
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

7.  Novel FKS mutations associated with echinocandin resistance in Candida species.

Authors:  Guillermo Garcia-Effron; Daniel Joseph Chua; Jon Rupert Tomada; Joseph DiPersio; David S Perlin; Mahmoud Ghannoum; Hector Bonilla
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

8.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction.

Authors:  Kelley R Healey; Santosh K Katiyar; Shriya Raj; Thomas D Edlind
Journal:  Mol Microbiol       Date:  2012-08-22       Impact factor: 3.501

10.  Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

Authors:  George R Thompson; Nathan P Wiederhold; Ana C Vallor; Nyria C Villareal; James S Lewis; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.